JP2000500026A5 - - Google Patents

Download PDF

Info

Publication number
JP2000500026A5
JP2000500026A5 JP1998505691A JP50569198A JP2000500026A5 JP 2000500026 A5 JP2000500026 A5 JP 2000500026A5 JP 1998505691 A JP1998505691 A JP 1998505691A JP 50569198 A JP50569198 A JP 50569198A JP 2000500026 A5 JP2000500026 A5 JP 2000500026A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998505691A
Other languages
English (en)
Japanese (ja)
Other versions
JP3681401B2 (ja
JP2000500026A (ja
Filing date
Publication date
Priority claimed from FR9608851A external-priority patent/FR2751343B1/fr
Application filed filed Critical
Publication of JP2000500026A publication Critical patent/JP2000500026A/ja
Publication of JP2000500026A5 publication Critical patent/JP2000500026A5/ja
Application granted granted Critical
Publication of JP3681401B2 publication Critical patent/JP3681401B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50569198A 1996-07-16 1997-07-15 感染性組換えウイルスの保存方法、水性ウイルス懸濁液、および薬剤としての使用 Expired - Lifetime JP3681401B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/08851 1996-07-16
FR9608851A FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
PCT/FR1997/001308 WO1998002522A1 (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Publications (3)

Publication Number Publication Date
JP2000500026A JP2000500026A (ja) 2000-01-11
JP2000500026A5 true JP2000500026A5 (Direct) 2004-10-21
JP3681401B2 JP3681401B2 (ja) 2005-08-10

Family

ID=9494078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50569198A Expired - Lifetime JP3681401B2 (ja) 1996-07-16 1997-07-15 感染性組換えウイルスの保存方法、水性ウイルス懸濁液、および薬剤としての使用

Country Status (11)

Country Link
US (2) US6451256B1 (Direct)
EP (1) EP0853660B1 (Direct)
JP (1) JP3681401B2 (Direct)
AT (1) ATE231549T1 (Direct)
AU (1) AU711409B2 (Direct)
CA (1) CA2232604C (Direct)
DE (1) DE69718612T2 (Direct)
DK (1) DK0853660T3 (Direct)
ES (1) ES2187798T3 (Direct)
FR (1) FR2751343B1 (Direct)
WO (1) WO1998002522A1 (Direct)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
JP2002531418A (ja) * 1998-12-03 2002-09-24 アビジェン， インコーポレイテッド アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
AU778894B2 (en) * 1999-04-09 2004-12-23 Centelion S.A.S. Composition for the preservation of infectious recombinant adenoviruses
FR2791999B1 (fr) * 1999-04-09 2001-09-07 Aventis Pharma Sa Composition destinee a la conservation d'adenovirus recombinants infectieux
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001085928A1 (en) * 2000-05-10 2001-11-15 Mitsubishi Pharma Corporation Method of preparing virus vector
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
KR20040077878A (ko) * 2002-01-18 2004-09-07 쉐링 악티엔게젤샤프트 아데노바이러스의 안정화된 제제
KR100507794B1 (ko) * 2003-02-11 2005-08-17 한미약품 주식회사 고농도 레트로 바이러스 현탁액 제조 방법
US20070148765A1 (en) * 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
EP1869171B2 (en) * 2005-04-11 2015-10-14 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
JP5770633B2 (ja) 2008-11-03 2015-08-26 クルセル ホランド ベー ヴェー アデノウイルスベクターの産生方法
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CN103269716B (zh) * 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EP2827895B1 (en) 2012-03-22 2017-08-09 Janssen Vaccines & Prevention B.V. Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EA029492B1 (ru) 2012-07-10 2018-04-30 Трансген Са Вакцина на основе микобактериальных антигенов
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
AU2014283334B2 (en) 2013-06-17 2018-10-18 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN106103471B (zh) 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 异源寡聚分枝杆菌抗原的融合
US9721484B2 (en) 2014-06-23 2017-08-01 Humanetics Innovative Solutions, Inc. Shoulder kit assembly for crash test dummy
EP3169341B1 (en) 2014-07-16 2019-06-05 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
US10008130B2 (en) 2014-09-17 2018-06-26 Humanetics Innovative Solutions, Inc. Omni-directional shoulder assembly for crash test dummy
WO2016128542A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
JP6735288B2 (ja) 2015-04-14 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
DK3439672T3 (da) 2016-04-05 2021-02-15 Janssen Vaccines & Prevention Bv Stabiliserede opløselige præfusions-rsv-f-proteiner
JP7046835B2 (ja) 2016-05-12 2022-04-04 ヤンセン ファッシンズ アンド プリベンション ベーフェー 強力でバランスのとれた双方向性プロモーター
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018049248A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
CA3053212C (en) 2017-02-09 2021-04-13 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CN111163800A (zh) 2017-09-15 2020-05-15 扬森疫苗与预防公司 用于安全诱导针对rsv的免疫的方法
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US12263197B2 (en) 2018-10-30 2025-04-01 The University Of Tokyo Oncolytic virus for cancer therapy
CA3117275A1 (en) 2018-11-13 2020-05-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US20230075527A1 (en) 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
CN115484985A (zh) 2020-03-19 2022-12-16 崔泽尔有限公司 温度响应病毒储存系统
CA3189238A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
WO2022161502A1 (zh) 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
EP4547705A1 (en) 2022-07-01 2025-05-07 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
WO1995010601A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
FR2711523B1 (fr) * 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations

Similar Documents

Publication Publication Date Title
JP2001510326A5 (Direct)
JP2001506095A5 (Direct)
JP2000501599A5 (Direct)
JP2000501018A5 (Direct)
JP2001504499A5 (Direct)
JP2000500076A5 (Direct)
JP2001509135A5 (Direct)
JP2000501324A5 (Direct)
JP2000500055A5 (Direct)
JP2000500026A5 (Direct)
JP2000501338A5 (Direct)
JP2000500874A5 (Direct)
JP2000506123A5 (Direct)
JP2000507578A5 (Direct)
JP2000500912A5 (Direct)
JP2000513148A5 (Direct)
JP2000501229A5 (Direct)
JP2000504876A5 (Direct)
JP2000500857A5 (Direct)
JP2000501569A5 (Direct)
JP2000500184A5 (Direct)
JP2000500318A5 (Direct)
JP2001500457A5 (Direct)
JP2002501364A5 (Direct)
JP2000500662A5 (Direct)